Complex regional pain syndrome (CRPS) is a chronic pain condition that usually affects an arm or leg. Additionally, it can sometimes affect other parts of the body like face, neck and trunk. It causes persistent, severe and unreasonable pain, swelling, changes in skin temperature and texture. The signs and symptoms are usually present in the area of the body affected and in the surrounding area. Symptoms also involve changes in skin color and temperature of the affected area. Non-pharmacological therapies such as physiotherapy, occupational therapy, psychological therapy and pain management programmes are being increasingly adopted for treating CRPS. The global complex regional pain syndrome market is estimated to be valued at US$ 103.7 million in 2023 and is expected to exhibit a CAGR of 7.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The growing adoption of non-pharmacological therapies for treating CRPS is expected to drive the growth of global complex regional pain syndrome market during the forecast period. Non-pharmacological therapies help in managing symptoms, improving mobility, and reducing pain without using medications. Moreover, these therapies also help in preventing complications and improving quality of life. For instance, physiotherapy helps in improving mobility and reducing stiffness through supervised exercise programs. Occupational therapy uses strategies to manage daily activities that may be affected due to pain and medical conditions associated with CRPS. Psychological therapies include cognitive behavioral therapy that helps patients cope with symptoms and changes associated with chronic pain. Additionally, pain management programs provide education about pain and teach coping strategies for reducing stress and improving sleep, which further aids in pain management.
The complex regional pain syndrome market can be segmented based on treatment type and end user. Based on treatment type, the market is segmented into medications, therapy, and others. The medications segment is dominating the market as medications are the first line of treatment for complex regional pain syndrome. Medications help reduce pain and inflammation.
Political: Government regulations around the approval of new drugs and therapies for complex regional pain syndrome can impact the market. Favorable regulatory environment fosters innovation.
Economic: Rising healthcare spending worldwide is fueling market growth. However, high cost of newer treatment options also acts as a restraint.
Social: Growing awareness about complex regional pain syndrome and its treatment options is supporting the market expansion. Also, rise in trauma and accidental injury cases leading to CRPS augments the demand.
Technological: Advancements in drug delivery systems and therapies are improving the treatment outcomes for complex regional pain syndrome. Developments in neuromodulation therapies are expanding the market possibilities.
The global complex regional pain syndrome market share is expected to witness high growth during the forecast period of 2023 to 2030. Regional analysis shows that North America currently dominates the market due to large patient pool and high healthcare expenditure. Europe follows next due to increasing initiatives for CRPS awareness.
Key players operating in the complex regional pain syndrome market are Intercos S.p.A., Kolmar Korea Co. Ltd., Scalpi CosmÃ©tica sa, Cosmecca Korea Co., Cosmax Inc., Mana Products Inc., KBL cosmetics Ltd., Urist Cosmetics Incorporated, Fareva Holding SA, Milliona Cosmetics Co., Ltd., Skinlys, Maesa SAS, SchwanhÃ¤uÃŸer Holding GmbH & Co. KG, Tricorbraun Inc., Herrco Cosmetics Limited, Architectural Beauty, Allure Labs Inc., Case Mason Filling, Inc., Pardaco Trading Pte Ltd, and KDC/ONE among others. The key players are focusing on new product innovations and launches to consolidate their market position.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it